Tina Chan Reich is a member of the Board of Directors of BILL Holdings Inc. (NYSE: BILL), an S&P MidCap400 SaaS technology company. She is a member of the Board of Directors of Santander Holdings USA, Inc. and Santander Bank, N.A. She serves on the Board of BAWAG Group (VIE: BG), an Austrian bank. She serves as a board observer and advisor to Medius, a European-based SaaS company as well as to Clara, a Latin American fintech company, and serves as an advisor to a number of global fintech, investment and PE/VC companies. She served on the Board of Altus Power, Inc. (NYSE: AMPS), and also served on the board of Citicorp Payment Services. She is a former Global Chief Credit Officer, Chief Risk Officer and Chief Data Scientist with various leadership positions in credit, payments, technology, digital transformation, and AI/ML. She is a recipient of the 100 AAPI Board Members Making a Difference Award 2024. She is also a member of the MIT Schwarzman College of Computing Dean’s Advisory Council. She is a graduate of MIT.

Pearl Huang, Ph.D.has more than 30 years of leadership experience in biotech and is currently the President and CEO of Dunad Therapeutics. Dr. Huang earned a bachelor’s degree in biology from MIT and her PhD in molecular biology from Princeton University. Her career began in 1990 as a bench scientist in Cancer Research at Merck Research Labs in West Point, PA, where she lived nearby with her family for 23 years. Dr. Huang moved to GlaxoSmithKline in Upper Providence, PA, as VP of Biology for the MMPD CEDD in 2001 before returning to Merck to serve as VP and Oncology Franchise Integrator in 2006, a strategic role heading up translational medicine to create the then-nascent oncology pipeline. In 2010, Pearl left Merck and co-founded Beigene in China, serving as CSO until 2012. She then returned to big pharma, holding additional leadership roles at GlaxoSmithKline and Roche pRED Basel. Collectively, Dr Huang has contributed to 9 programs that have gone from the discovery stage to medicines. She championed and led the BRAF and MEK programs at GSK, and guided the then Merck PARP inhibitor, niraparib, into the clinic. At GSK, Merck and Roche, Dr. Huang served on governing boards responsible for advancing preclinical projects across all therapeutic areas into Phase I and from Phase I into Phase II clinical proof of concept studies. In 2019, Dr. Huang joined Flagship Pioneering as a Venture Partner and CEO and President of Cygnal Therapeutics, which became Sonata Therapeutics. She left Sonata Therapeutics in April 2022 to join Dunad Therapeutics.

Pearl is a member of two public boards: the Waters Corp board (WAT, since 2021) where she chairs the Science and Technology Committee and is a member of the Nominations and Governance Committee, and the BB Biotech Board (SWX:BION, since 2022) where she chairs the Audit and Risk Committee. Pearl and her husband, J. Peter Hobbs, a chemical engineer, were the founding donors for the Huang-Hobbs Biomaker center at MIT, and she also serves as a term member of the MIT Corporation (2021-2025).

Kathy currently serves as President and CEO of Electra Therapeutics and is an Independent Director on the Board of Neuron23. Previously, she was COO of Star Therapeutics, where she held strategic and operational responsibilities across the Star portfolio, including building Electra Therapeutics and Vega Therapeutics from discovery stage into the clinic. Prior to joining Star, Kathy served as Head of Commercial Development at True North Therapeutics, and following its acquisition by Bioverativ/Sanofi, she advanced numerous programs through preclinical and clinical development as Head of New Product Planning. Kathy spent the initial nine years of her career at Gilead Sciences, where she led the launch and market development of numerous products, including SOVALDI and HARVONI, two of the most successful launches in biopharmaceutical history.

Dr. J. Jean Cui is a renowned oncology drug designer who is the lead inventor of 3 FDA approved medicines and multiple clinical compounds. She is the scientific founder, President and CEO of BlossomHill Therapeutics, Inc. Prior to BlossomHill, Dr. Cui is the scientific founder of Turning Point Therapeutics, Inc., a San Diego based biotech company focusing on turning point medicines for cancer patients. Turning Point went public on NASDAQ in April 2019. In June 2022, Bristol Myers Squibb announced the acquisition of Turning Point for $4.1 billion. Dr. Cui served as Turning Point’s Chief Scientific Officer (October 2013-January 2020) and a member of the Board of Directors. Prior to that, she was Senior Principal Scientist and then Associate Research Fellow at Pfizer (2003-2013). Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation (1999-2003).

Dr. Cui has made significant contributions in oncology drug discovery and development. As scientific founder of Turning Point, she focused on solving drug resistance issues in targeted therapies and invented a unique macrocyclic platform to systematically address resistance issues. This novel strategy and approach led to the creation of one FDA approved drug and two clinical compounds: Repotrectinib, TPX-0022, and TPX-0046 within 6 years since founding the company. Repotrectinib received 3 FDA Breakthrough Therapy Designations, 3 FDA Fast-Track designations, and 1 FDA Orphan Drug Designation. On November 15, 2023, FDA approves Repotrectinib (AUGTYROTM) for locally advanced or metastatic ROS1+ NSCLC. At Pfizer, Dr. Cui was the lead inventor of Crizotinib (XALKORITM) and Lorlatinib (LORBRENATM), and worked on several other oncology projects, including SUTENTTM.

Dr. Cui is an elected Member of the National Academy of Engineering (2024). Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011. She received 2 Pfizer Worldwide R&D Achievement Awards (2006 and 2012) and Pfizer innovation award in 2011. Dr. Cui was an honoree for the 2013 American Chemical Society (ACS)’s Heroes of Chemistry Program for the discovery and development of Crizotinib. Dr. Cui received her 2nd Heroes of Chemistry Award from ACS in 2021 for the discovery and development of Lorlatinib. Dr. Cui received the 2022 Distinguished Alumni Achievement Award from her Ph.D. alma mater. She received 2022 San Diego BioPharma Achievement Award from SABPA. Dr. Cui is the recipient of the 2023 Distinguished Scientist Award by ACS San Diego Section. She was an honoree for the Committee of 100 Circle of Excellence Award in Humanity in Science & Technology in 2023.

Dr. Cui received her Ph.D. from Ohio State University, and her M.S. and B.S. from University of Science and Technology of China. She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California Berkeley.

Dr. Judy Chou is the CEO and President of AltruBio, Inc. which is a clinical stage biotech company in San Francisco, CA. Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s biotechnology pipeline, product portfolio over 3+ billion net revenue & 2000+ employees.

She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018 by San Francisco Business Times.

Before Bayer, Dr. Chou held the role of Vice President of Pharmaceutical Operations at Pfizer, Inc. She was also Vice President of R&D and Manufacturing at Tanvex Biopharma and has enabled the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in drug development and multiple filings of BLAs, NDAs, and INDs of novel products and is broadly recognized for her work at Medivation, Genentech, Pfizer (Wyeth) and Abbvie (Abbott) especially in the development of breakthrough technologies and accelerated product development.

Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc. (NASDAQ: AKRO) and California Institute of Regenerative Medicines (CIRM); and the Advisory Board members of UC Berkeley Engineering School and Silicon Valley Women in Engineering. Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany